Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies. Issue 4 (24th June 2020)

• Record Type: Journal Article
• Authors: Amitai, Irina; Rozovski, Uri; El‐Saleh, Reem; Shimony, Shai; Shepshelovich, Daniel; Rozen‐Zvi, Benaya; Raanani, Pia; Gafter‐Gvili, Anat; Gurion, Ronit
• Is Part Of: Hematological oncology. Volume 38:Issue 4(2020)
• Page Start: 584
• Page End: 588
• Publication Date: 2020-06-24
• Subjects: acute kidney injury -- albumin -- lactic dehydrogenase -- methotrexate -- survival; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2759
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: High dose methotrexate (HDMTX)‐induced acute kidney injury (AKI) is a well‐known adverse event in hemato‐oncology patients. Our purpose was to define factors and setup cut‐offs that may help better identify patients at‐risk for developing AKI following HDMTX. All consecutive patients who received MTX dose ≥1 g were retrospectively reviewed. We compared patients with or without renal toxicity. We used a logistic regression model to define baseline variables associated with AKI. Overall survival (OS) was estimated by the Kaplan‐Meier method employing log‐rank test. Between 2012 and 2017, 160 patients were included with a total of 265 courses. Indications included: primary central nervous system (CNS) lymphoma, CNS prophylaxis in other lymphoma types, acute lymphatic leukemia and others. Median age at diagnosis was 58 years (range, 18‐84), 54% were males, median MTX dose was 1941 mg/m 2 (range, 743‐5442) and AKI developed in 9% of drug administrations (n = 24). In univariate analysis: age > 40, LDH > 380 units/L, eGFR < 112 mL/min, albumin <3.6 mg/dL at baseline and Charlson comorbidity index (CCI) were associated with AKI. In multivariable analysis, only LDH > 380 units/L (OR = 4.1, 95% confidence interval [CI] 1.04‐20.9, P = .04) and albumin levels <3.6 g/dL (OR = 4.17, 95% CI 1.04‐6.5, P = .04) remained significant. In patients with AKI, median drug elimination was longer (8 days vs 5 days). In 80% of cases, the creatinine levels returned to normal within 1 month. Yet, the median survival of patients who developed AKI was 37 months, compared to 145 months in patients without AKI (Log rank = 0.015). In conclusion, LDH > 380 units/L and albumin <3.6 g/dL were the strongest factors associated with AKI in patients receiving HDMTX. Although the rise in creatinine levels was almost uniformly reversible, AKI was associated with increased mortality rates.